Clarivate Plc filings document the financial reporting, governance and capital structure of a Jersey-incorporated public company that provides enriched data, analytics, workflow solutions and expert services across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Current reports furnish quarterly and annual earnings releases, supplemental revenue, earnings and guidance materials, and Regulation FD presentations.
The company's SEC records also cover proxy governance and executive compensation matters, including annual meeting disclosures and executive severance plan terms. Other filings describe financing arrangements involving subsidiaries, credit agreement amendments, senior secured note redemption and satisfaction and discharge, and related material-event disclosures under the Exchange Act.
CLARIVATE PLC (symbol: CLVT) is the issuer of record for a Form 4 filing submitted to the SEC.
CLARIVATE PLC (CLVT) Chief Executive Officer Shem Tov Matitiahu S. reported an automatic share disposition related to equity compensation. On 2026-08-13, 47,633 Ordinary Shares were withheld at $1.96 per share to satisfy tax obligations upon vesting of restricted share units, rather than sold in an open-market trade. Following this tax-withholding event, the CEO directly holds 2,290,782 Ordinary Shares and has an additional 320,603 Ordinary Shares held indirectly through IBI Trust Management.
Clarivate PLC executive Matthew J. Lisowski, Senior VP and Chief Accounting Officer, reported his beneficial ownership of the company’s ordinary shares. The filing shows direct ownership of 79,898 Ordinary Shares, with no specific buy or sell transaction reported in connection with this statement.
Kenneth L. Cornick, a director of Clarivate PLC, reported substantial insider purchases. An entity he and his spouse manage, Cornick Family Investor, LLC, purchased a total of 900,000 Ordinary Shares in early August 2026 at prices around $1.85–$1.86 per share. He also reports direct ownership of 112,686 Ordinary Shares.
Clarivate Plc director Andrew M. Snyder reported that affiliated Cambridge Information Group entities sold 2,489,618 ordinary shares of Clarivate on August 3, 2026 at a weighted average price of $1.94 per share, with individual sale prices ranging from $1.90 to $2.02.
After these sales, entities associated with Snyder continued to hold large indirect positions in Clarivate, including 10,178,764, 6,819,742 and 3,856,597 shares, plus additional direct and indirect holdings. Snyder disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Clarivate plc is the issuer in a notice covering potential sales of its ordinary shares under a Form 144 filing. The planned transactions are to be executed through J.P. Morgan Securities LLC on the NYSE.
The shares were originally acquired on December 1, 2021 as consideration in connection with the merger of ProQuest LLC into Clarivate. The filing references 2,489,618 ordinary shares tied to that merger consideration, indicating these previously issued shares may be sold in the market.
Clarivate Plc announced a finance leadership transition. Executive Vice President & Chief Financial Officer Jonathan Collins resigned effective August 7, 2026, with the company stating his departure is not due to any disagreement. Michael Easton, age 53, will become Executive Vice President & Chief Financial Officer effective August 8, 2026.
Easton, a longtime finance executive at Clarivate, currently serves as Senior Vice President, Finance & Chief Accounting Officer. His new package includes a $600,000 base salary, a target annual bonus equal to 100% of salary, 2027 long‑term equity incentives with a $2,000,000 target value, and a $750,000 one‑time promotion equity award. Clarivate also promoted Matthew Lisowski, age 40, to Senior Vice President, Chief Accounting Officer effective August 8, 2026, with revised salary, bonus and equity incentives.
Clarivate Plc reported softer results for the quarter ended June 30, 2026. Revenue was $587.3 million, down 5% year over year, with declines across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. A non‑cash goodwill impairment of $221.7 million in the LS&H segment drove a quarterly net loss of $268.6 million and a year‑to‑date loss of $308.8 million.
Despite lower revenue, Adjusted EBITDA was $247.2 million in Q2 with a 42.1% margin, and first‑half operating cash flow was $233.4 million, yielding Free cash flow of $122.9 million. Total debt declined to $4.25 billion after redeeming $100 million of 2026 notes and repurchasing portions of 2028 and 2029 notes. In July 2026 the company agreed to sell its LS&H business for $600.0 million (mostly cash), and management states it plans to use proceeds to reduce debt and focus on the A&G and IP segments; LS&H will be reported as a discontinued operation beginning in the third quarter of 2026.
Clarivate Plc reported Q2 2026 results with revenues of $587.3 million, down 5.5% year over year, mainly from divestitures and weaker transactional demand. Organic revenues declined 1.5% as 0.7% organic subscription growth was offset by a 15.7% drop in organic transactional revenues.
Profitability was mixed. A $221.7 million non‑cash goodwill impairment tied to the Life Sciences & Healthcare segment drove a net loss of $268.6 million, or $0.42 per diluted share, versus a $72.0 million loss a year earlier. Adjusted net income was $123.1 million and Adjusted EBITDA was $247.2 million, both slightly below Q2 2025, while the Adjusted EBITDA margin held at 42.1%. First‑half free cash flow was $122.9 million.
The balance sheet and strategy are shifting. Total debt fell to $4,251.5 million at June 30, 2026, a $218.4 million reduction in the first half, and cash was $217.7 million. Clarivate reached a definitive agreement to sell its Life Sciences & Healthcare segment to Altaris LLC at 10x expected 2026 Adjusted EBITDA less capex, with net proceeds intended for debt repayment and a pro forma recurring revenue mix of about 92%. The company reaffirmed its 2026 outlook, including revenues including discontinued operations of $2.30–$2.42 billion, Adjusted EBITDA of $980–$1,040 million, Adjusted diluted EPS of $0.70–$0.80 and free cash flow of $365–$435 million.
Clarivate Plc has entered into a definitive agreement to sell its Life Sciences & Healthcare business to an affiliate of Altaris, LLC for an aggregate purchase price of $600,000,000. The deal is expected to close by the end of calendar year 2026, subject to regulatory approvals and other customary conditions and does not require shareholder approval.
The consideration includes $500,000,000 in cash at closing (subject to customary adjustments), $25,000,000 of deferred consideration payable no later than January 31, 2028, and a $75,000,000 unsecured senior note issued by a buyer affiliate. Buyer financing is supported by Altaris equity and debt commitments, with a $33,000,000 termination fee payable by Buyer in specified circumstances.
Clarivate will also enter a transition services agreement and related commercial arrangements to support post-closing operations. Separately, a retention agreement for Henry Levy, President, Life Sciences & Healthcare, provides accelerated vesting of certain equity upon closing and severance protections if he is terminated without cause within six months after closing.